ALMS: Oppenheimer Adjusts Price Target Following Merger Approval | ALMS Stock News

Author's Avatar
May 15, 2025

Oppenheimer has revised its price target for Alumis (ALMS, Financial), reducing it slightly from $26 to $25 while maintaining an Outperform rating for the company's shares. This adjustment comes after Alumis and Acelyrin received shareholder approval for their merger, a deal anticipated to be finalized in the second quarter. Investors are advised to stay informed about such developments, which can impact stock valuation and market performance.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.